SCHEMBL3623201

SCHEMBL3623201

O=Cc1c[nH]c2nccc(-c3ccc(F)cc3F)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.46
LRRK2 Q5S007 1/20 0.45
PIM1 P11309 2/20 0.41
PIM3 Q86V86 1/20 0.41
KMT2A Q03164 1/20 0.41
AXL P30530 1/20 0.37
ROCK2 O75116 2/20 0.37
ROCK1 Q13464 1/20 0.37
CDC42BPB Q9Y5S2 1/20 0.37
KMO O15229 1/20 0.36
CDC7 O00311 1/20 0.36
MAP4K4 O95819 1/20 0.36
PRKACA P17612 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3B P49841 1/20 0.36
HIPK2 Q9H2X6 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
TRPA1 O75762 3/20 0.36
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952362 0.78 KMT2A (0.51) JAK2LRRK2KMT2AROCK2ROCK1
SCHEMBL3566122 0.76 HSP90AB1 (0.43) JAK2LRRK2PIM3KMT2AROCK2
SCHEMBL29935820 0.74 KMT2A (0.49) JAK2LRRK2PIM1PIM3KMT2A
SCHEMBL21428928 0.74 KMT2A (0.49) JAK2LRRK2PIM1PIM3KMT2A
SCHEMBL839505 0.73 KMT2A (0.39) JAK2LRRK2PIM1PIM3KMT2A
SCHEMBL29953748 0.73 LRRK2 (0.57) JAK2LRRK2KMT2AAXLROCK2
SCHEMBL29957196 0.73 KMT2A (0.56) JAK2LRRK2PIM1PIM3KMT2A
SCHEMBL856933 0.73 LRRK2 (0.47) LRRK2PIM1PIM3KMT2AAXL
SCHEMBL15805274 0.73 LRRK2 (0.44) JAK2LRRK2PIM1PIM3AXL
SCHEMBL15805288 0.73 SIK1 (0.60) JAK2LRRK2PIM1PIM3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US claimed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
EP-2057155-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS Vernalis (R&D) Limited (GB) 2009-05-13 EP disclosed
WO-2008025947-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2008-03-06 WO disclosed
WO-2008025947-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P JAK2 303/4885LRRK2 2502/4885PIM1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.